Metallothioneins (MTs) are low molecular, cysteine-rich proteins that have naturally-occurring Zn(2+) in both clusters. They may serve as a reservoir of metals for synthesis of apoenzymes and zinc-finger transcription regulators. MTs are also involved with several important proteins e.g. p53, NF-kappaB, PKCl, and GTPase Rab3A. New biological roles for these proteins have been identified including those needed in the carcinogenic process. However, their use as a predictive marker remains controversial. Several reports have disclosed MTs expression as a prognostic factor for tumor progression and drug resistance in a variety of malignancies particularly breast, prostatic, ovarial, head and neck, non-small cell lung cancer, melanoma, and soft tissue sarcoma. The role of MTs as a tumor disease marker or as a cause of resistance in cancer treatment is reviewed and discussed. Moreover, we describe some analytical methods that were developed to detect MTs.

Department of Chemistry and Biochemistry Mendel University of Agriculture and Forestry Zemedelska 1 Brno CZ 613 00 Czech Republic

000      

02502naa 2200409 a 4500

001      

bmc11022318

003      

CZ-PrNML

005      

20121127124650.0

008      

110729s2009 ne e Eng||

009      

AR

040    __

$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a ne

100    1_

$a Eckschlager, Tomáš, $d 1956- $7 jn20000400613

245    10

$a Metallothioneins and cancer / $c T. Eckschlager, V. Adam, J. Hraběta, K. Figová, R. Kizek

314    __

$a Department of Chemistry and Biochemistry, Mendel University of Agriculture and Forestry, Zemedelska 1, Brno CZ-613 00, Czech Republic.

520    9_

$a Metallothioneins (MTs) are low molecular, cysteine-rich proteins that have naturally-occurring Zn(2+) in both clusters. They may serve as a reservoir of metals for synthesis of apoenzymes and zinc-finger transcription regulators. MTs are also involved with several important proteins e.g. p53, NF-kappaB, PKCl, and GTPase Rab3A. New biological roles for these proteins have been identified including those needed in the carcinogenic process. However, their use as a predictive marker remains controversial. Several reports have disclosed MTs expression as a prognostic factor for tumor progression and drug resistance in a variety of malignancies particularly breast, prostatic, ovarial, head and neck, non-small cell lung cancer, melanoma, and soft tissue sarcoma. The role of MTs as a tumor disease marker or as a cause of resistance in cancer treatment is reviewed and discussed. Moreover, we describe some analytical methods that were developed to detect MTs.

590    __

$a bohemika - dle Pubmed

650    _2

$a zvířata $7 D000818

650    _2

$a antitumorózní látky $x farmakologie $7 D000970

650    _2

$a cytostatické látky $x farmakologie $7 D054697

650    _2

$a chemorezistence $7 D019008

650    _2

$a lidé $7 D006801

650    _2

$a metalothionein $x analýza $x biosyntéza $x chemie $x metabolismus $7 D008668

650    _2

$a nádory $x farmakoterapie $x metabolismus $x patofyziologie $7 D009369

655    _2

$a přehledy $7 D016454

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Adam, Vojtěch, $d 1982- $7 xx0064599

700    1_

$a Hraběta, Jan $7 xx0127445

700    1_

$a Figová, Katarína $7 xx0074407

700    1_

$a Kizek, René, $d 1972- $7 jn20001005291

773    0_

$t Current Protein & Peptide Science $w MED00007895 $g Roč. 10, č. 4 (2009), s. 360-375

910    __

$a ABA008 $b x $y 2

990    __

$a 20110801131010 $b ABA008

991    __

$a 20121127124716 $b ABA008

999    __

$a ok $b bmc $g 881711 $s 732237

BAS    __

$a 3

BMC    __

$a 2009 $x MED00007895 $b 10 $c 4 $d 360-375 $m Current protein and peptide science $n Current Protein & Peptide Science

LZP    __

$a 2011-4B09/jvme